ACY-1083

Research use only, not for human use.

ACY-1083 is a selective and brain-penetrating HDAC6 inhibitor (IC50: 3 nM). It is 260-fold more selective for HDAC6 than all other classes of HDAC isoforms.

ACY-1083 is a selective and brain-penetrating HDAC6 inhibitor (IC50: 3 nM). It is 260-fold more selective for HDAC6 than all other classes of HDAC isoforms. ACY-1083 effectively reverses chemotherapy-induced peripheral neuropathy.(In Vitro):ACY-1083 (30 and 300 nM) dose-dependently improves cell viability.(In Vivo):In C57BL/6J mice, ACY-1083 (10 mg/kg; i.p.) effectively relieves Cisplatin-induced mechanical allodynia. In adult male SD rats, ACY-1083 (3 mg/kg; orally) reverses Paclitaxel-induced mechanical allodynia. ACY-1083(5 mg/kg; i.p.) shows a Cmax of 936 ng/mL, a half-life (T1/2) of 3.5h, and a biologically active plasma exposure of 8 hours.

——

Cell Cycle/DNA Damage

HDAC

antibacterial

——

——

1708113-43-2

348.4

C17H18F2N4O2

>98% (HPLC)

——

ONC(=O)c1cnc(NC2(CCC(F)(F)CC2)c2ccccc2)nc1

——

(-20℃)

With Ice Pack

≥ 2 years